Patent classifications
A61K9/1682
DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF
The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.
Bendamustine pharmaceutical compositions
Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
SPRAY-DRIED HUMAN PLASMA
The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.
GOLF BALL-LIKE MICROPARTICLES FOR USE IN THE TREATMENT AND PREVENTION OF PULMONARY DISEASES
The present invention relates to a golf ball-like microparticles obtained by atomization of nanosuspensions of nanoparticles or solutions for dry powder inhalers for use in the treatment and prevention of pulmonary diseases.
STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES
Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.
Treatment method for colon cancer
The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe.sub.3O.sub.4, as well as compositions containing HSS.
SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF
The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.
WATER-DISPERSIBLE DRY POWDER FORMULATION AND PRODUCTION METHOD THEREOF
Disclosed herein is a water-dispersible dry powder formulation that includes, based on the total weight of the water-dispersible dry powder formulation, 0.2 wt % to 4.0 wt % of glucagon, 10 wt % to 95.0 wt % of lactose, 0.001 wt % to 5.0 wt % of acetone, and 0.1 wt % to 10.0 wt % of water. The water-dispersible dry powder formulation has a pH value ranging from 2.0 to 6.0. A method for producing the water-dispersible dry powder formulation is also disclosed.
Composition having improved flowabilty and methods for making and using the composition
Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.
FLOW CHANNEL STRUCTURE FOR REMOVING FOREIGN SUBSTANCE, METHOD FOR REMOVING FOREIGN SUBSTANCE, AND METHOD FOR MANUFACTURING LIPID PARTICLES
A flow channel structure for removing a foreign substance, including a first flow channel, where the first flow channel has a first region having a depth shallower than a depth of another region. A method for removing a foreign substance in a fluid, including flowing the fluid to the first flow channel of the flow channel structure for removing a foreign substance.